The definitions in this section apply throughout this chapter
unless the context clearly requires otherwise:
(1) "Amniocentesis" means a procedure to
remove a small amount of amniotic fluid from the uterus of a pregnant person in
order to perform one or more of the following laboratory tests:
(a) Measure the level of
alpha-fetoprotein;
(b) Measure the
level of acetylcholinesterase;
(c)
Cytogenetic studies on fetal cells including chromosome analysis, cytogenomic
microarray analysis (CMA), and fluorescent in-situ hybridization
(FISH);
(d) Biochemical studies on
fetal cells or amniotic fluid;
(e)
Deoxyribonucleic acid (DNA) studies on fetal cells for single gene disorders or
fetal genotyping for isoimmunization studies; and
(f) Infectious disease studies.
(2) "Carrier screening" means a
procedure to remove blood or other tissue from one or both parents in order to
perform laboratory analysis to establish chromosome constitution or recessive
or X-linked genetic carrier status of the parents.
(3) "Chorionic villus sampling" means a
procedure to remove a small number of cells from the developing placenta, in
order to perform one or more of the following laboratory tests:
(a) Cytogenetic studies on fetal cells
including chromosome analysis, cytogenomic microarray analysis (CMA), and
fluorescent in-situ hybridization (FISH);
(b) Biochemical studies on placental cells;
and
(c) DNA studies on placental
cells for single gene disorders.
(4) "Hepatitis B surface antigen (HBsAg)
screening" means a procedure involving obtaining blood from a pregnant person
to test for maternal hepatitis B infection.
(5) "Maternal serum marker screening" means a
procedure involving obtaining blood from a pregnant person in order to measure
through laboratory tests the level of certain products that are associated with
increased risks to the fetus or pregnancy such as alpha-fetoprotein,
unconjugated estriol, human gonadotropin, inhibin, or PAPP-A.
(6) "Percutaneous umbilical blood sampling"
means a procedure to obtain blood from the fetus, in order to perform one or
more of the following laboratory tests:
(a)
Cytogenetic studies on fetal cells including chromosome analysis, cytogenomic
microarray analysis (CMA), and fluorescent in-situ hybridization
(FISH);
(b) Viral titer
studies;
(c) Fetal blood typing for
isoimmunization studies;
(d)
Prenatal diagnostic tests for hematological disorders;
(e) DNA studies on fetal cells for single
gene disorders; and
(f) Biochemical
studies on fetal blood.
(7) "Postprocedure genetic counseling" means
individual counseling that may be part of another procedure, or service
involving a health care provider and a pregnant person with or without other
family members, to discuss the results of the prenatal tests done, any further
testing or procedures available or referrals for further consultation or
counseling.
(8) "Prenatal cell free
DNA screening," sometimes called noninvasive prenatal screening, means drawing
blood from the pregnant person to perform laboratory analysis on the cell free
DNA circulating in the maternal blood stream.
(9) "Prenatal test" means any test or
procedure to screen for or diagnose congenital or heritable disorders of a
fetus.
(10) "Prenatal
ultrasonography " means a procedure resulting in visualization of the uterus,
the placenta, the fetus, and internal structures through use of sound
waves.
(11) "Preprocedure genetic
counseling" means individual counseling that may be part of another procedure,
or service, involving a health care provider and a pregnant person with or
without other family members, to assess and identify increased risks for
congenital abnormalities or pregnancy complications, offer specific carrier
screening or diagnostic tests, discuss the purposes, risks, accuracy, and
limitations of a prenatal testing procedure, aid in decision making and to
assist, when necessary, in obtaining the desired testing or
procedure.